Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
316.67
+6.00 (1.93%)
At close: May 12, 2025, 4:00 PM
315.00
-1.67 (-0.53%)
After-hours: May 12, 2025, 7:28 PM EDT
Insulet Revenue
Insulet had revenue of $569.00M in the quarter ending March 31, 2025, with 28.82% growth. This brings the company's revenue in the last twelve months to $2.20B, up 23.49% year-over-year. In the year 2024, Insulet had annual revenue of $2.07B with 22.07% growth.
Revenue (ttm)
$2.20B
Revenue Growth
+23.49%
P/S Ratio
10.10
Revenue / Employee
$563,821
Employees
3,900
Market Cap
22.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
PODD News
- 8 hours ago - 20 stocks of companies showing excellent earnings-season trends even as the economy cools - Market Watch
- 3 days ago - S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks - Investopedia
- 3 days ago - Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More - Investopedia
- 3 days ago - Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad - Benzinga
- 3 days ago - Insulet Is the Top S&P 500 Performer Today. Here's Why. - Barrons
- 3 days ago - Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Insulet beats quarterly profit estimates on insulin pump demand - Reuters
- 4 days ago - Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1) - Business Wire